Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer

Trial Profile

Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2011 New trial record
    • 01 Dec 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top